Oncology Experts

William Windsor

Adjunct Professor
Stevens Institute of Technology
United States of America


Adjunct Professor and Visiting Scholar in the Department of Biomedical Engineering, Chemistry and Biological Sciences. Directs the CHI Biophysical Chemistry Lab for Drug Discovery and was most recently the Director of the Biochemistry & Biophysics Department at the Merck Research Laboratory and Director of Kinase Research at Schering-Plough Research Institute (SPRI). He has over 30 years’ experience in preclinical drug discovery and is an expert in biochemical and biophysical analysis of protein-ligand / protein-protein interactions, enzymology and structure-based drug design to elucidate the mechanism of action of small molecule inhibitors. Dr. Windsor has extensive experience in methods of calorimetry (ITC, DSC), circular dichroism, absorbance and fluorescence spectroscopy and protein purification. Dr. Windsor is recognized as one of the first scientists at SPRI to develop an expertise in protein kinase biochemistry and due to his experience and leadership skills became the Chairman of a100 member cross-functional Protein Kinase Working Group which developed state of the art methods to discover and develop clinical kinase inhibitor drugs. His preclinical research focused on oncology and immunology/inflammation diseases. Noted outstanding accomplishments include the development of seven clinical drugs including: Sarasar (FPT inhibitor for Progeria and Oncology), HCV protease inhibitor Boceprevir, kinase inhibitors Dinaciclib (CDK2) and ERK inhibitor SCH 900353. Dr. Windsor was awarded the Schering-Plough Presidential Research Award for the discovery of Dinaciclib and for the X-ray Structure of FPT and is an author and co-inventor for over 50 publications and patents. Honors & Awards

Research Interest

Drug Discovery for Oncology Targets.


  • Lu Z, Cox-Hipkin MA, Windsor WT, Boyapati A (2010) 3-Phosphoinositide–Dependent Protein Kinase-1 Regulates Proliferation and Survival of Cancer Cells with an Activated Mitogen-Activated Protein Kinase Pathway. Molecular Cancer Research 8: 421-432.

  • Zhang R, Windsor WT (2013) In vitro kinetic profiling of hepatitis C virus NS3 protease inhibitors by progress curve analysis. Antiviral Methods and Protocols 59-79.

Global Experts from United States of America

Global Experts in Subject

Share This Profile
Recommended Conferences